Anshul Maheshwari Sells 11,228 Shares of SiBone (NASDAQ:SIBN) Stock

SiBone (NASDAQ:SIBN) insider Anshul Maheshwari sold 11,228 shares of the business’s stock in a transaction on Friday, August 21st. The stock was sold at an average price of $20.02, for a total transaction of $224,784.56. Following the sale, the insider directly owned 234,920 shares in the company, valued at approximately $4,703,098.40. The trade was a 4.56% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Anshul Maheshwari also recently made the following trade(s):

• On Wednesday, August 19th, Anshul Maheshwari sold 5,747 shares of SiBone stock. The shares were sold at an average price of $19.55, for a total value of $112,353.85.
• On Monday, August 17th, Anshul Maheshwari sold 4,665 shares of SiBone stock. The shares were sold at an average price of $18.65, for a total value of $87,002.25.
• On Thursday, July 2nd, Anshul Maheshwari sold 3,317 shares of SiBone stock. The stock was sold at an average price of $16.77, for a total value of $55,626.09.

SiBone Price Performance

SIBN traded up $0.48 on Friday, reaching $19.96. The stock had a trading volume of 1,290,316 shares, compared to its average volume of 620,561. SiBone has a fifty-two week low of $11.48 and a fifty-two week high of $21.89. The firm has a 50-day moving average of $17.40 and a 200-day moving average of $15.30. The company has a current ratio of 9.15, a quick ratio of 7.55 and a debt-to-equity ratio of 0.20. The company has a market capitalization of $885.21 million, a price-to-earnings ratio of -58.71 and a beta of 0.66.

SiBone (NASDAQ:SIBN) last announced its quarterly earnings results on Monday, August 3rd. The company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.06. The firm had revenue of $56.01 million for the quarter, compared to analyst estimates of $55.34 million. SiBone had a negative return on equity of 8.23% and a negative net margin of 6.85%. As a group, sell-side analysts anticipate that SiBone will post -0.4 EPS for the current year.

Institutional Trading of SiBone

Several institutional investors have recently added to or reduced their stakes in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in SiBone by 4.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,426 shares of the company’s stock valued at $343,000 after purchasing an additional 1,053 shares during the period. Dynamic Technology Lab Private Ltd acquired a new position in shares of SiBone in the 1st quarter worth approximately $225,000. Goldman Sachs Group Inc. boosted its stake in shares of SiBone by 28.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 379,757 shares of the company’s stock valued at $5,328,000 after purchasing an additional 83,919 shares during the last quarter. Jane Street Group LLC bought a new stake in shares of SiBone in the 1st quarter valued at $1,818,000. Finally, Legal & General Group Plc increased its position in shares of SiBone by 16.1% during the second quarter. Legal & General Group Plc now owns 42,403 shares of the company’s stock worth $798,000 after buying an additional 5,888 shares during the period. 98.11% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on SIBN shares. TD Cowen boosted their target price on shares of SiBone from $18.00 to $20.00 and gave the stock a “buy” rating in a report on Tuesday, August 4th. UBS Group lifted their price target on shares of SiBone from $24.00 to $25.00 and gave the stock a “buy” rating in a report on Tuesday, August 4th. Truist Financial reissued a “buy” rating and issued a $23.00 price objective (up from $21.00) on shares of SiBone in a research note on Tuesday, August 4th. Finally, Weiss Ratings upgraded SiBone from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday. Six equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $24.17.

SiBone Company Profile

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.